GSA Capital Partners LLP Sells 686,963 Shares of Ocugen, Inc. $OCGN

GSA Capital Partners LLP reduced its stake in Ocugen, Inc. (NASDAQ:OCGN) by 39.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,041,598 shares of the company’s stock after selling 686,963 shares during the quarter. GSA Capital Partners LLP owned about 0.36% of Ocugen worth $1,698,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd bought a new stake in shares of Ocugen in the second quarter worth $333,000. Vanguard Personalized Indexing Management LLC grew its position in Ocugen by 48.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 29,871 shares of the company’s stock valued at $29,000 after buying an additional 9,791 shares during the period. Ethic Inc. purchased a new stake in Ocugen during the second quarter valued at approximately $40,000. Catalyst Funds Management Pty Ltd bought a new position in Ocugen in the second quarter worth approximately $130,000. Finally, Verdence Capital Advisors LLC bought a new position in Ocugen in the third quarter worth approximately $47,000. Institutional investors own 10.27% of the company’s stock.

Ocugen Stock Performance

NASDAQ:OCGN opened at $1.44 on Wednesday. The stock has a 50-day moving average price of $1.49 and a 200 day moving average price of $1.36. The stock has a market capitalization of $449.74 million, a P/E ratio of -6.55 and a beta of 3.49. Ocugen, Inc. has a 12-month low of $0.52 and a 12-month high of $1.96. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 8.04.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on OCGN shares. Weiss Ratings restated a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Ocugen in a research report on Tuesday, January 20th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.00.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.